| ABCB1、CES1 和 CYP2C19 基因多态性与
氯吡格雷抵抗的相关性研究进展 |
| |
| 引用本文： | 李嘉欣.ABCB1、CES1 和 CYP2C19 基因多态性与
氯吡格雷抵抗的相关性研究进展[J].微生物学杂志,2015(11). |
| |
| 作者姓名： | 李嘉欣 |
| |
| 作者单位： | 1. 中国药科大学药学院 , 江苏 南京 211198; 2. 南京医科大学附属南京医院临床药理实验室，江苏 南京 210006 |
| |
| 基金项目： | 国家自然科学基金 （No. 30901830） |
| |
| 摘 要： | 氯吡格雷是目前全球临床使用最为广泛的血小板受体抑制剂，但其抗血小板效应存在明显个体差异，部分病人服用常规剂量氯吡格
雷后存在抵抗现象，甚至发生不良临床事件。多项研究表明，ABCB1、CES1 和 CYP2C19 基因多态性对氯吡格雷抵抗的产生发挥重要作用。
简介氯吡格雷体内吸收与代谢机制和氯吡格雷抵抗的定义，综述 ABCB1、CES1 和 CYP2C19 基因多态性对氯吡格雷抵抗的影响。
|
| 关 键 词： | 氯吡格雷抵抗 ABCB1 基因 CES1 基因 CYP2C19 基因 基因多态性 |
Research Progress in the Correlation between
ABCB1, CES1 and CYP2C19 Gene Polymorphisms and
Clopidogrel Resistance |
| |
| LI Jiaxin.Research Progress in the Correlation between
ABCB1, CES1 and CYP2C19 Gene Polymorphisms and
Clopidogrel Resistance[J].Journal of Microbiology,2015(11). |
| |
| Authors: | LI Jiaxin |
| |
| Institution: | 1. School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2. Clinical Pharmacology Laboratory, Nanjing Hospital Affiliated
to Nanjing Medical University, Nanjing 210006, China |
| |
| Abstract: | Clopidogrel is one of the most widely clinically used platelet receptor inhibitors in the world, but there exists significant individual
difference in its anti-platelet effect. Clopidogrel resistance, even adverse clinical events, could be presented in some patients taking common doses
of clopidogrel. Several studies have shown that ABCB1, CES1 and CYP2C19 gene polymorphisms play a key role in clopidogrel resistance. the
mechanisms of in vivo clopidogrel absorption and metabolism and the definition of clopidogrel resistance were introduced. The impacts of ABCB1,
CES1 and CYP2C19 gene polymorphisms on clopidogrel resistance were reviewed. |
| |
| Keywords: | clopidogrel resistance ABCB1 gene CES1 gene CYP2C19 gene gene polymorphism |
|
| 点击此处可从《微生物学杂志》浏览原始摘要信息 |
| 点击此处可从《微生物学杂志》下载免费的PDF全文 |
